NewAmsterdam Pharma Company N.V. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
NewAmsterdam Pharma Company N.V. (NAMS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $18.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $18.38M, a 21.09% increase year-over-year.
- NewAmsterdam Pharma Company N.V. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $18.00M, a 18.33% increase year-over-year.
- NewAmsterdam Pharma Company N.V. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $15.01M, a 87.34% increase year-over-year.
- NewAmsterdam Pharma Company N.V. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $15.18M, a 82.07% increase year-over-year.
- NewAmsterdam Pharma Company N.V. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $59.42M, a 76.18% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $33.73M, a 36.22% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $24.76M, a 472.24% increase from fiscal 2022.
- NewAmsterdam Pharma Company N.V. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.33M, a 502.65% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.38M 10-Q · filed 2026-08-05 | $36.38M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $18.00M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $59.42M 10-K · filed 2026-02-18 | |||
| 2025-09-30 | $15.01M 10-Q · filed 2025-11-05 | $30.19M derived: sum of 2 quarters · filed 2026-08-05 | $45.40M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $15.18M 10-Q · filed 2026-08-05 | $30.39M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $15.21M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $33.73M 10-K · filed 2026-02-18 | |||
| 2024-09-30 | $8.01M 10-Q · filed 2025-11-05 | $16.35M derived: sum of 2 quarters · filed 2025-11-05 | $24.31M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $8.34M 10-Q · filed 2025-11-05 | $16.30M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $7.96M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $24.76M 10-K · filed 2026-02-18 | |||
| 2023-09-30 | $5.44M 10-Q · filed 2024-11-06 | $11.04M derived: sum of 2 quarters · filed 2024-11-06 | $18.71M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $5.61M 10-Q · filed 2024-11-06 | $13.27M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $7.66M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $4.33M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $718.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |